Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy

被引:232
|
作者
Carr, A [1 ]
Marriott, D
Field, A
Vasak, E
Cooper, DA
机构
[1] St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia
[2] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Dept Anat Pathol, Sydney, NSW 2010, Australia
[4] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
来源
LANCET | 1998年 / 351卷 / 9098期
关键词
D O I
10.1016/S0140-6736(97)07529-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Enterocytozoon bieneusi and Cryptosporidium parvum? cause chronic antimicrobial-resistant gastrointestinal infections in HIV-1-infected individuals. HIV-1 reverse transcriptase inhibitors delay the onset of opportunistic infections, but are not known to reverse: established infections. HIV-1 protease inhibitors are more effective across a broader range of HIV-l-infected immune cells. Combination antiretroviral[ therapy that includes a protease inhibitor could improve immunity to E bieneusi and C:parvum, Methods HIV-1 infected patients with chronic microsporidiosis (five), cryptosporidiosis (three), or dual infection lane), were treated with combination therapy that included at least one HIV-1 protease inhibitor, Outcome measures were symptoms weight, use of antidiarrhoeal and antimicrobial drugs, T-lymphocyte subsets, HIV-1 viraemia! stool microscopy, and biopsy by endoscopy. Findings Ail patients had complete clinical responses, gained a median 15 hg in weight, and ceased ail antidiarrhoeal and antimicrobial therapies, Biliary cryptosporidiosis responded in both affected patients, Neither pathogen was detected in follow-up stool microscopy (eight of eight patients) or in biopsy samples by endoscopy (five of five), Intestinal architecture returned to normal in three patients, There was a dense CD8 lymphocyte and macrophage infiltrate and staining of intraepithelial E bieneusi with interferon-gamma before and after treatment, but little staining for CD4 or B lymphocytes, interleukin 10, or HIV-1 gp41., Five patients remained symptom-free after a median 13 months' follow-up, Four patients had recurrent diarrhoea at 7-13 months (one with positive stool microscopy), associated with declining CD4 counts. Interpretation Combination antiretroviral therapy that includes a protease inhibitor can restore immunity to E bieneusi or C parvum in HIV-1 infected individuals, and result in complete clinical, microbiological, and histological responses, The persistent CD8 cell and macrophage infiltrate, and the rapid time to relapse in patients with declining CD4 lymphocyte counts, suggest that neither infection was eradicated.
引用
收藏
页码:256 / 261
页数:6
相关论文
共 50 条
  • [1] Timing of Antiretroviral Therapy for HIV-1-Associated Tuberculosis
    Boyles, Tom H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (05): : 474 - 475
  • [2] Timing of Antiretroviral Therapy for HIV-1-Associated Tuberculosis REPLY
    Toeroek, M. Estee
    Farrar, Jeremy J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (05): : 476 - 476
  • [3] Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease
    Garvey, L.
    Winston, A.
    Walsh, J.
    Post, F.
    Porter, K.
    Gazzard, B.
    Fisher, M.
    Leen, C.
    Pillay, D.
    Hill, T.
    Johnson, M.
    Gilson, R.
    Anderson, J.
    Easterbrook, P.
    Bansi, L.
    Orkin, C.
    Ainsworth, J.
    Palfreeman, A.
    Gompels, M.
    Phillips, A. N.
    Sabin, C. A.
    NEUROLOGY, 2011, 76 (08) : 693 - 700
  • [4] Treatment of HIV among tuberculosis patients: A replication study of timing of antiretroviral therapy for HIV-1-associated tuberculosis
    Djimeu, Eric W.
    Heard, Anna C.
    PLOS ONE, 2019, 14 (02):
  • [5] HIV-1-associated nephropathy and response to highly-active antiretroviral therapy
    Wali, RK
    Drachenberg, CI
    Papadimitriou, JC
    Keay, S
    Ramos, E
    LANCET, 1998, 352 (9130): : 783 - 784
  • [6] Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Parveen, Zahida
    Acheampong, Edward
    Pomerantz, Roger J.
    Jacobson, Jeffrey M.
    Wigdahl, Brian
    Mukhtar, Muhammad
    CURRENT HIV RESEARCH, 2007, 5 (03) : 281 - 292
  • [7] The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction
    Kline, Erik R.
    Sutliff, Roy L.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (05) : 752 - 769
  • [8] Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1
    Maggi, P
    Larocca, AMV
    Quarto, M
    Serio, G
    Brandonisio, O
    Angarano, G
    Pastore, G
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (03) : 213 - 217
  • [9] Effect of Antiretroviral Therapy on Cryptosporidiosis and Microsporidiosis in Patients Infected with Human Immunodeficiency Virus Type 1
    P. Maggi
    A. M. V. Larocca
    M. Quarto
    G. Serio
    O. Brandonisio
    G. Angarano
    G. Pastore
    European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19 : 213 - 217
  • [10] Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment
    Tozzi, V
    Balestra, P
    Galgani, S
    Narciso, P
    Ferri, F
    Sebastiani, G
    D'Amato, C
    Affricano, C
    Pigorini, F
    Pau, FM
    De Felici, A
    Benedetto, A
    AIDS, 1999, 13 (14) : 1889 - 1897